Search
Ovid Therapeutics Inc
OVIDAdd to Watchlist
2.540USD
-0.010-0.39%
Close 11-13 16:00（ET）
496.06MMarket Cap
LossP/E TTM
Ovid Therapeutics Inc (OVID) Stock Price Target & Forecast
Analyst Rating
Based on 13 analysts giving stock ratings to Ovid Therapeutics Inc in the past month.
Strong Buy
7 Strong Buy
6 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
6.400USD+151.97%
OVID Analyst Recommendation Trends
In the current month, OVID has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. OVID average Analyst price target in the last month is 6.400.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
7
7
5
5
5
5
5
5
6
6
5
5
5
6
6
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13
13
10
10
10
11
11
10
OVID Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ascendis Pharma A/S
ASND
9
13
1
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, OVID EPS is projected to reach -0.099 in FY2026Q4, following reported EPS of -0.102 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.12
-0.12
-0.09
-0.10
-0.10
Actual
-0.12
-0.08
-0.10
--
--
Surprise
-3.74%
+37.18%
-16.97%
--
--
FAQs
What is Ovid Therapeutics Inc's expected revenue for the next quarter?
Ovid Therapeutics Inc's expected revenue is 82.25K.
What is Ovid Therapeutics Inc's price target?
Analysts forecast that Ovid Therapeutics Inc's price target is USD 6.40, with the highest forecast at USD 9.00 and the lowest forecast at USD 4.00.
How have Ovid Therapeutics IncOVID's recent earnings per share performed?
The market expectation was USD -0.10, while Ovid Therapeutics IncOVID's earnings per share (EPS) for the previous quarter was USD -0.08. EPS for the next quarter is expected at USD -0.10.
What is the analyst rating for Ovid Therapeutics Inc?
Based on the ratings of Ovid Therapeutics Inc's stock from 13 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.